A study for women who have ovarian cancer that has spread after treatment with a platinum-based chemotherapy
» ClinicalTrials.gov Identifier: NCT05870748
your doctor may refer to this as “platinum-resistant ovarian cancer”
If you have ovarian cancer with Folate Receptor alpha (FRα), you may have the chance to join this study and take an investigational therapy that’s designed for you¹
FRα is a protein that is very common in ovarian cancer cells²’³
REFRαME-O1 is a study of an investigational treatment called luveltamab tazevibulin that directly targets cancer cells with FRα¹
Sutro Biopharma created this study to give more
women the chance for targeted therapy¹
women with platinum-resistant ovarian cancer may be able to enroll in REFRαME-O11-3
IMPORTANT INFORMATION ABOUT THE STUDY
ARE YOU ABLE TO JOIN THE REFRαME-O1 STUDY?¹
To be eligible for REFRαME-O1, you need to have:
- Ovarian cancer that has spread after treatment with platinum-based chemotherapy (your doctor may refer to this as “platinum-resistant ovarian cancer”)
- Received no more than 3 previous treatments for your ovarian cancer
- 25% to 100% of your cancer cells have FRα on the surface (your doctor will test you)
WHAT MEDICINES WILL YOU RECEIVE?
In this trial, you will have the opportunity to receive the current standard of care chemotherapy for your ovarian cancer or targeted therapy with the investigational treatment, luveltamab tazevibulin¹
WHAT SHOULD YOU EXPECT DURING THE STUDY IF YOU ENROLL?
To help support your health throughout the study, your doctors will take regular blood tests and imaging tests¹
WHY IS THE REFRαME-O1 STUDY UNIQUE?¹
The REFRaME-O1 study is giving more women with FRα the chance to receive investigational therapy designed for them
WHO IS SUTRO?
Sutro Biopharma is an innovative drug company that designs and develops targeted cancer medicines for patients who need them the most
Ask your doctor if the REFRαME-O1 study is
right for you.
More information about Sutro and their studies can be found at sutrobio.com or email us directly at reframe@sutrobio.com
References: 1. Data on file. Sutro Biopharma, Inc. 2. Birrer MJ, Betella I, Martin LP, Moore KN. Is targeting the folate receptor in ovarian cancer coming of age? Oncologist. 2019;24(4):425-429. 3. Bax HJ, Chauhan J, Stavraka C, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128(2):342-353.
Copyright © 2024 Sutro Biopharma, Inc. South San Francisco, California, USA
